The interface of preclinical evaluation with clinical testing of antiepileptic drugs: role of pharmacogenomics and pharmacogenetics

Author： Holmes G.L.  

Publisher： Elsevier

ISSN： 0920-1211

Source： Epilepsy Research, Vol.50, Iss.1, 2002-06, pp. : 41-54

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Critical re-evaluation of previous preclinical strategies for the discovery and the development of new antiepileptic drugs

By Loscher W.   Leppik I.E.  

Epilepsy Research, Vol. 50, Iss. 1, 2002-06 ,pp. : 17-20

Elsevier

Access to resources Recommend Favorite

Do preclinical seizure models preselect certain adverse effects of antiepileptic drugs

By Meldrum B.  

Epilepsy Research, Vol. 50, Iss. 1, 2002-06 ,pp. : 33-40

Elsevier

Access to resources Recommend Favorite

Cancer risk in people with epilepsy: the role of antiepileptic drugs

By Singh Gagandeep  

Brain, Vol. 128, Iss. 1, 2005-01 ,pp. : 7-17

Oxford University Press

Access to resources Recommend Favorite

The clinical impact of new antiepileptic drugs after a decade of use in epilepsy

By Schmidt D.  

Epilepsy Research, Vol. 50, Iss. 1, 2002-06 ,pp. : 21-32

Elsevier

Access to resources Recommend Favorite

Evaluation and prediction of effects of antiepileptic drugs in a variety of other CNS disorders

By Lopes da Silva F.   Post R.M.  

Epilepsy Research, Vol. 50, Iss. 1, 2002-06 ,pp. : 191-193

Elsevier

Access to resources Recommend Favorite